PBX4 and bladder transitional cell carcinoma: For instance, the overexpression of PBX4 could prolong the survival of patients with BLCA, CESC, HNSC, KIRP, LIHC, LUAD, STAD, and THCA but shorten the survival of patients with KIRC and UCEC.